Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH. Hawkins DS, et al. Among authors: mccowage g. J Clin Oncol. 2018 Sep 20;36(27):2770-2777. doi: 10.1200/JCO.2018.77.9694. Epub 2018 Aug 9. J Clin Oncol. 2018. PMID: 30091945 Free PMC article. Clinical Trial.
Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.
White L, McCowage G, Kannourakis G, Nayanar V, Colnan L, Kellie S, Shaw P, Seshadri R, Lockwood L, Tiedemann K, et al. White L, et al. Among authors: mccowage g. J Clin Oncol. 1994 Mar;12(3):522-31. doi: 10.1200/JCO.1994.12.3.522. J Clin Oncol. 1994. PMID: 8120550 Clinical Trial.
A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group.
Carpenter PA, White L, McCowage GB, Nayanar V, Toogood I, Shaw PJ, Lockwood L, Tiedemann K. Carpenter PA, et al. Among authors: mccowage gb. Cancer. 1997 Aug 1;80(3):489-96. doi: 10.1002/(sici)1097-0142(19970801)80:3<489::aid-cncr17>3.0.co;2-t. Cancer. 1997. PMID: 9241083 Clinical Trial.
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK; Children’s Oncology Group. Baker DL, et al. N Engl J Med. 2010 Sep 30;363(14):1313-23. doi: 10.1056/NEJMoa1001527. N Engl J Med. 2010. PMID: 20879880 Free PMC article. Clinical Trial.
Treatment of children with poor risk solid tumors by further escalation of the VETOPEC regimen including very high-dose cyclophosphamide and peripheral stem cell support: an Australian and New Zealand Children's Hematology and Oncology Group study.
McCowage GB, Mrongovius R, Alvaro F, Cohn RJ, Ziegler DS, Oswald C, White L; Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG). McCowage GB, et al. Pediatr Blood Cancer. 2011 Dec 1;57(6):958-64. doi: 10.1002/pbc.23042. Epub 2011 Jul 25. Pediatr Blood Cancer. 2011. PMID: 21793175 Clinical Trial.
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Grill J, et al. Among authors: mccowage g. J Clin Oncol. 2018 Apr 1;36(10):951-958. doi: 10.1200/JCO.2017.76.0611. Epub 2018 Feb 7. J Clin Oncol. 2018. PMID: 29412784 Clinical Trial.
Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Harrison DJ, Chi YY, Tian J, Hingorani P, Mascarenhas L, McCowage GB, Weigel BJ, Venkatramani R, Wolden SL, Yock TI, Rodeberg DA, Hayes-Jordan AA, Teot LA, Spunt SL, Meyer WH, Hawkins DS, Shulkin BL, Parisi MT. Harrison DJ, et al. Cancer Med. 2021 Feb;10(3):857-866. doi: 10.1002/cam4.3667. Epub 2020 Dec 19. Cancer Med. 2021. PMID: 33340280 Free PMC article.
83 results